The Asia-Pacific Artificial Intelligence (AI) in drug discovery market was valued at USD 660.36 million in 2025 and is projected to reach USD 17,753.93 million by 2033, growing at a CAGR of 50.9% from 2026 to 2033. The market is witnessing strong expansion driven by increasing adoption of AI-powered platforms in pharmaceutical research, rising investments in precision medicine, and growing demand for faster and cost-efficient drug development processes across emerging and developed economies in the region.
The growing burden of chronic and complex diseases, coupled with the need to reduce the time and cost associated with traditional drug discovery, is accelerating the integration of machine learning, deep learning, and generative AI tools in early-stage research. In addition, supportive government initiatives for digital healthcare, expanding biotech startup ecosystems, and collaborations between pharmaceutical companies and AI technology providers are further boosting adoption. AI-driven target identification, lead optimization, and predictive modeling are increasingly becoming essential components of modern drug discovery workflows across Asia-Pacific markets.